Navigation Links
Senetek Announces Termination of Invicorp(R) License Agreement With Ardana Bioscience Limited
Date:7/3/2008

NAPA, Calif., July 3 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced termination of the Invicorp(R) License Agreement with Ardana Bioscience Limited ("Ardana"). The Agreement was a license to manufacture, market, sell and distribute Invicorp(R) in Europe and was terminated pursuant to the Company's contractual rights, precipitated by Ardana's entry into voluntary administration on June 27, 2008.

Mr. Frank Massino, Senetek's Chairman and Chief Executive Officer stated, "We have advised Ardana of the Invicorp(R) License termination and served demand for return of all related clinical and regulatory data. We have received a number of inquiries regarding the availability of the European license and we are confident this will be a valuable and productive asset in the hands of the right partner".

Invicorp(R), is a highly safe and effective treatment for erectile dysfunction ("ED"), a condition that affects more than 100 million men worldwide. Invicorp(R) is expected to capture a significant share of the moderate-to-severe ED market and become the therapy of choice for second-line ED treatment. Invicorp(R) has received marketing authorization in Denmark as well as in England. Additionally, Invicorp(R) has been approved in New Zealand. Senetek has entered into an exclusive licensing and collaborative marketing agreement for the commercialization of Invicorp(R) with Plethora Solutions for the North American market.

About Senetek PLC

Senetek PLC (OTC Bulletin Board: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market.For more information, visit the company's website at http://www.senetekplc.com.

This news release contains statements that may be considered 'forward- looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2007. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Senetek PLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Senetek Announces Plan for Promotion, Sales and Distribution of Pyratine-6(TM)
2. Senetek PLC Resolves Dispute With Marketer of Pyratine-6(TM) on Most Favorable Terms
3. Senetek PLC Announces Key Personnel Appointments
4. Senetek PLC Reports 2007 Financial Results
5. Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts
6. Senetek PLC Announces Launch of New Website
7. Senetek PLC Announces Debut of Pyratine-6(TM) at the Annual Meeting of the American Academy of Dermatology
8. Senetek PLC Reports Third Quarter 2007 Financial Results
9. Mylan Announces Tentative FDA Approval for Generic Version of Antibiotic Zyvox(R) Tablets
10. Hooper Holmes Announces Sale of Claims Evaluation Division
11. Transition Therapeutics Announces Executive Management Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important to ... Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed a ... or restricted lighting. As such, it eliminates the need to turn on a light ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual ... in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon ... fun run is geared towards children of all ages; it is a non-competitive, non-timed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... today announced that its MyDario product is expected to appear on The ... when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz ... The ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/22/2017)... Md. , Sept. 22, 2017  As the ... Republican Senators Bill Cassidy (R-LA) and ... Information notes that the medical device industry is in ... medical device tax, the 2.3% excise tax on medical ... But they also want covered patients, increased visits and ...
Breaking Medicine Technology: